Dooley S, Kolobova E, Burman A, Kaji I, Digrazia J, Stubler R
Gastroenterology. 2024; 168(1):84-98.e9.
PMID: 39299401
PMC: 11663138.
DOI: 10.1053/j.gastro.2024.09.007.
Tsubaki M, Takeda T, Matsuda T, Kishimoto K, Tanaka R, Tsurushima K
Clin Exp Med. 2022; 23(5):1597-1607.
PMID: 36451049
DOI: 10.1007/s10238-022-00951-9.
Lin Z, Tang X, Cao Y, Yang L, Jiang M, Li X
Aging (Albany NY). 2022; 14(22):9264-9279.
PMID: 36445333
PMC: 9740379.
DOI: 10.18632/aging.204405.
Viale M, Lentini G, Gangemi R, Castagnola P, Milani G, Ravera S
Molecules. 2022; 27(22).
PMID: 36431971
PMC: 9695310.
DOI: 10.3390/molecules27227870.
Steiro I, Vandsemb E, Elsaadi S, Misund K, Sponaas A, Borset M
Oncotarget. 2022; 13:1175-1186.
PMID: 36268559
PMC: 9584456.
DOI: 10.18632/oncotarget.28300.
2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.
Khamaisi H, Mahmoud H, Mahajna J
Molecules. 2022; 27(3).
PMID: 35164068
PMC: 8839885.
DOI: 10.3390/molecules27030804.
The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting to Elucidate the Synergistic Pathway of Survivin with P-Glycoprotein in Cancer Multi-Drug Resistance.
Deng C, Hu F, Zhao Z, Zhou Y, Liu Y, Zhang T
Front Cell Dev Biol. 2022; 9:797005.
PMID: 35047507
PMC: 8762277.
DOI: 10.3389/fcell.2021.797005.
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.
Allegra A, Ettari R, Innao V, Bitto A
Cells. 2021; 10(2).
PMID: 33672466
PMC: 7923438.
DOI: 10.3390/cells10020448.
Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells.
Tabata M, Tsubaki M, Takeda T, Tateishi K, Tsurushima K, Imano M
BMC Complement Med Ther. 2020; 20(1):84.
PMID: 32171300
PMC: 7076888.
DOI: 10.1186/s12906-020-2879-8.
Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells.
Tsubaki M, Takeda T, Noguchi M, Jinushi M, Seki S, Morii Y
Cancers (Basel). 2019; 11(12).
PMID: 31769426
PMC: 6966459.
DOI: 10.3390/cancers11121866.
Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
Tabata M, Tsubaki M, Takeda T, Tateishi K, Maekawa S, Tsurushima K
Clin Exp Med. 2019; 20(1):63-71.
PMID: 31650359
DOI: 10.1007/s10238-019-00587-2.
Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation.
Zhou Q, Song C, Liu X, Qin H, Miao L, Zhang X
Cancer Manag Res. 2019; 11:625-636.
PMID: 30666159
PMC: 6331075.
DOI: 10.2147/CMAR.S191353.
RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Mashimo K, Tsubaki M, Takeda T, Asano R, Jinushi M, Imano M
Clin Exp Med. 2018; 19(1):133-141.
PMID: 30291461
DOI: 10.1007/s10238-018-0531-4.
CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.
Zhang T, Ma K, Huang J, Wang S, Liu Y, Fan G
Oncotarget. 2018; 8(66):110052-110063.
PMID: 29299129
PMC: 5746364.
DOI: 10.18632/oncotarget.22123.
Polysaccharide-based nanoparticles for co-loading mitoxantrone and verapamil to overcome multidrug resistance in breast tumor.
Xu Y, Asghar S, Gao S, Chen Z, Huang L, Yin L
Int J Nanomedicine. 2017; 12:7337-7350.
PMID: 29066886
PMC: 5644570.
DOI: 10.2147/IJN.S145620.
Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.
Jinesh G, Manyam G, Mmeje C, Baggerly K, Kamat A
Sci Rep. 2017; 7(1):9602.
PMID: 28851898
PMC: 5575243.
DOI: 10.1038/s41598-017-08796-z.
Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.
Ding J, Yuan L, Chen G
Oncol Lett. 2017; 13(2):647-654.
PMID: 28356941
PMC: 5351279.
DOI: 10.3892/ol.2016.5472.
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.
Yang H, Du X, Xi Y
Exp Ther Med. 2016; 12(2):771-776.
PMID: 27446274
PMC: 4950835.
DOI: 10.3892/etm.2016.3401.
RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
Tsubaki M, Takeda T, Yoshizumi M, Ueda E, Itoh T, Imano M
Tumour Biol. 2016; 37(7):9099-110.
PMID: 26762414
DOI: 10.1007/s13277-015-4761-8.
Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.
de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab A
Leuk Lymphoma. 2015; 57(7):1677-86.
PMID: 26421357
PMC: 5925422.
DOI: 10.3109/10428194.2015.1099645.